Streetbeat News

Stock Prices

PSNL

Personalis, Inc. (NASDAQ:PSNL) announced initial findings from its work with the TRACERx lung cancer study, demonstrating a significant advancement in lung cancer circulating tumor DNA (ctDNA) detection and management. The Personalis NeXT Personal cancer assay, designed to detect and monitor residual and recurrent disease (MRD), showed significantly improved detection rates for early-stage lung cancer.

Portfolio Pulse from Charles Gross

October 22, 2023 | 3:25 pm

AGEN

Agenus Inc. (NASDAQ:AGEN) announced expanded data from its phase 1b study of botensilimab and balstilimab in patients with advanced sarcomas. The results showed a 40% 6-month PFS, 20% ORR, and a 63% disease control rate. The median duration of response was 19.4 months.

Portfolio Pulse from Charles Gross

October 22, 2023 | 3:23 pm

BTCUSD

ETHUSD

LTCUSD

Crypto analyst Tone Vays has warned traders to be cautious despite Bitcoin's recent 10% increase in value, expressing doubts about its potential to sustain this momentum and hit the $32,000 mark. He also predicted a potential fall for Bitcoin to around $28,000. Vays also pointed out a potential double-bottom pattern forming against Bitcoin for Ethereum, predicting challenges ahead for the cryptocurrency. He also anticipated a continued decline in Litecoin's value relative to Bitcoin.

Portfolio Pulse from Bibhu Pattnaik

October 22, 2023 | 3:21 pm

RVMD

Revolution Medicines, Inc. (NASDAQ:RVMD) announced promising anti-tumor and safety data for RMC-6236, its RASMULTI(ON) Inhibitor, in patients with previously treated non-small cell lung cancer and pancreatic ductal adenocarcinoma. The drug demonstrated preliminary evidence of clinical activity and an acceptable safety profile across several dose levels and KRASG12X genotypes.

Portfolio Pulse from Charles Gross

October 22, 2023 | 3:06 pm

HOOK

Hookipa Pharma Inc. (NASDAQ:HOOK) has announced preliminary data from its ongoing Phase 2 trial of HB-200 in combination with pembrolizumab in patients with HPV16+ head and neck cancer. The data showed a 42% objective response rate and a disease control rate of 74% across 19 patients, doubling the response rate for pembrolizumab alone. The company plans to start a randomized trial of HB-200 in combination with pembrolizumab as a 1st-line treatment in 2024.

Portfolio Pulse from Charles Gross

October 22, 2023 | 2:27 pm

FFND

TSLA

Tesla shares dropped following disappointing quarterly results and management's commentary. Investors are losing confidence in Tesla's long-term growth and fear further price cuts. Future Fund's Gary Black suggests Tesla should focus on accelerating EV adoption and executing growth initiatives, rather than relying on price cuts. He also advocates for a $100 million education campaign to inform potential EV buyers about the benefits of EVs.

Portfolio Pulse from Shanthi Rexaline

October 22, 2023 | 2:15 pm

MSFT

PLTR

TSLA

This week in AI news, controversies and investor enthusiasm took center stage. Elon Musk accused Sam Altman of 'stealing' the internet, leading to a Twitter skirmish. AI stocks, including Palantir Technologies and C3.ai, have seen significant growth, but analysts favor one over the other. NYC Mayor Eric Adams has been using AI voice cloning software for multilingual phone calls. A study revealed that AI chatbots can deduce personal details from user inputs, raising privacy concerns. Microsoft CEO Satya Nadella called for philosophical guidance on AI due to fears of manipulation.

Portfolio Pulse from Benzinga Neuro

October 22, 2023 | 12:00 pm

AAPL

Apple Inc. (NASDAQ:AAPL) had a busy week with developments including TV show cancellations, iPhone 15 Pro Max glitches, CEO Tim Cook's talks with Chinese officials, product timeline updates, and the launch of a new, more affordable Apple Pencil. Apple TV+ cancelled 'The Problem With Jon Stewart' due to creative differences. Apple's customer support suggested that a bug in the iOS 17 beta update might be causing the iPhone 15 Pro Max's display burn-in issue. Amid concerns over a potential iPhone ban and the declining market in China, Tim Cook met with China's commerce minister Wang Wentao. Tech analyst Ming-Chi Kuo suggested that the mass production of Apple's AirTag 2 might be delayed to 2025. Apple launched a new, cost-effective Apple Pencil with a USB-C port.

Portfolio Pulse from Benzinga Neuro

October 22, 2023 | 11:14 am

ASML

NVDA

The US is imposing restrictions on the procurement of vital spare parts for chip equipment to slow down China's progress in the semiconductor sector. This move is part of a broader effort to deter China's technological strides in the semiconductor realm, following Huawei's launch of a 5G smartphone equipped with an advanced 7-nanometer chip manufactured by SMIC. The US has also collaborated with Japan and the Netherlands to target China's acquisition of cutting-edge chipmaking technology and essential spare parts. Companies like ASML Holding NV and Nvidia Corporation are expected to benefit from these restrictions.

Portfolio Pulse from Nabaparna Bhattacharya

October 22, 2023 | 1:44 am

BLK

BTCUSD

DOGEUSD

This week's cryptocurrency news focused on Dogecoin's potential to reach $16, rising hopes for a Bitcoin ETF approval, and Anthony Scaramucci's bold prediction for Bitcoin's value. Crypto Analyst AMINSHEYBANI predicted that Dogecoin could surge over 27,000% and potentially reach $16. Ark Invest's CEO Cathie Wood stated that hopes are rising for a Bitcoin ETF approval by the SEC. Anthony Scaramucci of SkyBridge Capital projected that Bitcoin's value could skyrocket 2,662%, potentially rivaling a $15 trillion asset class. BlackRock Inc’s CEO Larry Fink commented on the Bitcoin rally following a false report about their application for an iShares Bitcoin Trust ETF.

Portfolio Pulse from Benzinga Neuro

October 22, 2023 | 1:02 am